Abstract: AIMS: Inflammation plays a key role in acute coronary syndromes (ACS). Toll-like receptors (TLR) on leucocytes mediate inflammation and immune responses. We characterized leucocytes and TLR expression within coronary thrombi and compared cytokine levels from the site of coronary occlusion with aortic blood (AB) in ACS patients. METHODS AND RESULTS: In 18 ACS patients, thrombi were collected by aspiration during primary percutaneous coronary intervention. Thrombi and AB from these patients as well as AB from 10 age-matched controls without coronary artery disease were assessed by FACS analysis for cellular distribution and TLR expression. For further discrimination of ACS specificity, seven non-coronary intravascular thrombi and eight thrombi generated in vitro were analysed. In 17 additional patients, cytokine levels were determined in blood samples from the site of coronary occlusion under distal occlusion and compared with AB. In coronary thrombi from ACS, the percentage of monocytes related to the total leucocyte count was greater than in AB (47 vs. 20%, P = 0.0002). In thrombi, TLR-4 and TLR-2 were overexpressed on CD14-labelled monocytes, and TLR-2 was increased on CD66b-labelled granulocytes, in comparison with leucocytes in AB. In contrast, in vitro and non-coronary thrombi exhibited no overexpression of TLR-4. Local blood samples taken under distal occlusion revealed elevated concentrations of chemokines (IL-8, MCP-1, eotaxin, MIP-1alpha, and IP-10) and cytokines (IL-1ra, IL-6, IL-7, IL-12, IL-17, IFN-alpha, and granulocyte-macrophage colonystimulating factor) regulating both innate and adaptive immunity (all P < 0.05). CONCLUSION: In ACS patients, monocytes accumulate within thrombi and specifically overexpress TLR-4. Together with the local expression patterns of chemokines and cytokines, the increase of TLR-4 reflects a concerted activation of this inflammatory pathway at the site of coronary occlusion in ACS. 
Background
Acute coronary syndromes (ACS) represent the major clinical events in the natural history of coronary artery disease (CAD). 1 Evidence is accumulating that inflammatory processes contribute to the development of ACS. [2] [3] [4] [5] Activation of immune cells via different biological pathways leads to the production of inflammatory mediators 6 , thereby accelerating plaque vulnerability and eventually rupture. Toll-like receptors (TLR) are key regulators of both innate and adaptive immune responses. 7 Multiple endogenous ligands of TLR exist (e.g. heat shock proteins 8 , components of extracellular matrix 9 , fibrinogen 10 , myeloid-related protein 8/14 11 ) that activate the TLR signaling network 12 ; TLR-activation induces the production of proinflammatory cytokines (e.g. interleukin (IL) 6 (IL-6), IL-12, IL-1 β and tumor necrosis factor α (TNF-α) 12, 13 ), chemokines (e.g. IL-8 14 , monocyte chemoattractant protein 1 (MCP-1) 15 , macrophage inflammatory protein (MIP)-1α 16 , MIP-1β, eotaxin 17 , interferon-inducible protein-10 (IP-10) 18 ) as well as antimicrobial molecules such as nitric oxide. 19 These responses enable macrophages to eliminate invading microorganisms. Furthermore, after TLR-activation anti-inflammatory cytokines (e.g. IL-1 receptor antagonist (IL-1ra), IL-10 and IL-4 20 ) are released as well providing negative feedback regulation of the inflammatory response. TLR-induced expression of co-stimulatory molecules sustains the activation of adaptive immunity. 19 Multiple roles of TLR signaling in atherosclerosis have been postulated 21 , but the involvement of distinct members of the TLR family in the pathophysiology of ACS remains unknown.
Thus, we investigated in patients with ACS undergoing primary percutaneous intervention (PCI) the composition of inflammatory cells as well as the expression of TLR within the occluding thrombus relative to the systemic circulation and compared cytokine levels from the site of coronary occlusion with aortic blood. 
Methods
Due to different sampling procedures, cellular analysis with TLR-expression and cytokine levels were studied in two separate study populations (see Appendix 1) . The institutional ethics committee approved the protocol. Written informed consent was obtained from all patients.
Cellular analysis and TLR-expression

Study population 1
Eighteen ACS-patients with aspiration of macroscopically visible red thrombus during primary PCI and 10 patients with angiographically documented absence of coronary artery disease were consecutively studied.
Sample collection 1
Thrombus material was aspirated from the site of coronary occlusion during primary percutaneous coronary intervention (PCI) in patients with ACS using an Export ® XT 6F
Aspiration Catheter (Medtronic Inc., Minneapolis). The harvested thrombi were separated from blood with a sieve, placed in phosphate buffered saline (PBS), and immediately processed.
Analysis of cells within thrombi
The cellular content of thrombi and the TLR expression on the different cell types were assessed in patients with ACS. Thrombi were mechanically disrupted, cells resuspended in cell culture medium RPMI containing 10% FCS and 0,001% Actilyse® (to remove fibrin), and rotated for 24 h at 37°C before staining. Erythrolysis was performed by repetitive short mild osmotic shocks. The peripheral blood or thrombi mixture after incubation for 24h at 37°C with Actilyse were repeatly incubated with destilled water for 5-10 seconds; then PBS was added (1:9 water:PBS) and the cells were centrifuged. This procedure has been repeated 4-5 times at 4°C in order to reduce the amount of red blood cells before FACS analysis. The 
Analysis of aortic blood cells
Cell numbers were analyzed using standard procedures (using a Casy1 counter, Shäfer System, Reutlingen, Germany). The same incubation conditions, labeling procedures and flow cytometry analysis were applied for aortic blood cells, as for the cells isolated from thrombi.
Control thrombi
To separate thrombus-specific rather than ACS-specific mechanisms and to determine potential effects of coagulation products on TLR-expression, we analyzed thrombi generated in vitro, and in vivo thrombi from other clinical settings than ACS.
In vitro thrombi: Peripheral blood samples from eight healthy subjects were separated into two parts: 1. either 500 l of blood were incubated with 500 l recombinant tissue factor 
Measurement of Cytokine Levels
Study population 2
This group consisted of 17 patients presenting with ACS and an identifiable culprit lesion at angiography during primary PCI plus at least two of the following three criteria: 1) coronary occlusion, 2) thrombus formation, 3) impairment of the wall motion in the supplied territory by left ventricular angiography. Exclusion criteria were a serum level of C-reactive protein (CRP) ≥ 10 mg/L, myocarditis, pericarditis or a left ventricular ejection fraction of ≤35%.
Sample collection 2
Serum levels of inflammatory markers were assessed in blood samples obtained simultaneously from the site of coronary occlusion and the aorta. In all patients the culprit artery was intubated with a 7F guiding catheter and wired with the 0.014 inch PercuSurge™
GuardWire™ (Medtronic Inc., Minneapolis) as described. 6 An Export ® XT aspiration catheter was used to obtain local blood samples. To minimize potential dilution effects with saline, the EXPORT-catheter was immediately inserted without flushing over the PercuSurge GuardWire with the distal occlusion activated. The aspiration was started at the most distal point and stopped after one passage at the proximal point of the culprit coronary artery segment. Thus only the filling volume of the Export ® catheter might have caused a minor dilution with aortic blood. This protocol resulted in relatively small volumes (0.5-2.0 ml) of intracoronary blood however sufficient for processing and analysis with the multiplex technology (see below).
Only patients with poor flow (≤ TIMI grade I) after wire passage were included to ensure preserved local conditions.
Measurement of cytokines/chemokines and apoptosis markers
Twenty-five cytokines and chemokines were analyzed using bead-based multiplex determined using a multiplex assay capable of simultaneously quantifying these 6 analytes (Linco Res. Inc., Missouri). In addition, CRP was measured using a chemiluminescence immunoassay from Siemens diagnostics (formerly DPC) as previously reported. (GraphPad Software Inc., San Diego, CA). A probability value <0.05 was considered statistically significant.
Results
Cellular actors
Study population 1
Eighteen ACS-patients with aspiration of macroscopically visible red thrombus during primary PCI were consecutively studied. TIMI-0 flow (corresponding to a total occluded artery) was present in 17 of 18 patients (95%, TIMI-1 flow in one patient). Mean age was 58
(SD ± 12) years, 94% were males. No diabetics were included, dyslipidemia was present in 50% of the patients, arterial hypertension in 44%, 33% had a positive family history for premature cardiovascular events and 50% were smokers (Table 1) . Twenty-seven percent of the patients were on aspirin, clopidogrel-pretreatment was rare (6%). GP IIb/IIIa-inhibitors were initiated during PCI in 72% of the patients (33% abciximab, 39% tirofiban). Heparin was administered in 94%, one patient underwent the procedure with dalteparine. The aortic blood samples of the control population were taken from 10 age-matched healthy controls with a similar risk factor profile and angiographically documented absence of coronary artery disease. Patients with ACS underwent cardiac catheterization on average four hours after the onset of symptoms.
Cellular distribution of leukocytes in coronary thrombi versus aortic blood
The cellular composition of the intracoronary thrombi from patients with ACS (study population 1) differed significantly from blood obtained in the aorta at the same point in time. 
Cellular distribution of leukocytes in aortic blood of ACS patients versus controls
Absolute total white cell blood count was significantly elevated in ACS-patients ( 
Toll-like receptor expression
Leukocytes within coronary thrombi
There was a significantly increased TLR-4 expression (43% [20- Figure 2 ).
Control thrombi
In vitro thrombi: The control samples were treated in the same manner as cells of the thrombus, i.e. incubation with Actilyse for 24h at 37°C. The relative proportion of granulocytes is reduced by about 10% with this procedure, probably due to apoptosis.
However, the yield of cells obtained from thrombi for FACS analysis is increased thereby.
The procedure has no effect on the cell surface expression of TLR4, as substantiated in cells before and after treatment (in 3 cases). Over a time-course of 12 hours, the expression of TLR-4 on CD14+ monocytes remained in the same range as previously observed in aortic blood cells from controls (median mfi: 0h, 39; 1h, 41; 2h, 42; 4h, 42; 6h, 39; controls 45).
In vivo thrombi:
We collected six thrombi from patients with peripheral arterial occlusions. 
Influence of thrombus age on TLR-4 expression
We correlated the age of the thrombi, calculated according to the patients' history details, with TLR4-expression on monocytes. Regarding the whole timeline of collected thrombi (event-to-balloon time range from 45min to 5 days) no significant correlation between TLR4 mfi on CD14+ monocytes could be detected (Spearman's rank correlation coefficient r = 0.32, p=0.18). Even when including only thrombi of a probable age <12 hours (n=14) the correlation was very weak (Spearman's rank correlation coefficient r = 0.45, p=0.11).
Interestingly, in-vitro thrombi (not exposed to their natural enviroment of cytokines, extracelluar matrix, necrotic debris etc.) expressed TLR4 on CD14+ monocytes at a still lower level and did not show any upregulation over the first 12 hours (Spearman's rank correlation coefficient r = -0.23, p=0.66) (see Figure 3) .
Immunohistochemistry
TLR-4 expression was concentrated in distinct regions of the intracoronary thrombi ( Figure   4 ). There were groups of mainly mononuclear leukocytes with high expression, whereas in regions with mainly polymorphonuclear leukocytes almost no TLR-4 activity was observed.
Immunohistochemistry for TLR-2 demonstrated a reciprocal setting: regions with mainly polymorphonuclear leukocytes showed elevated TLR-2 activity, in contrast to mononuclear leukocytes clusters. In control thrombi, leukocytes showed generally a very weak TLR-4 expression. Furthermore, the nested appearance of leukocytes observed in intracoronary thrombi was missing, leukocytes in control thrombi appeared isolated within filamentous material and erythrocytes (see Appendix 6).
Cytokine levels
Patient characteristics of study population 2 are shown in Table 1 
Discussion
We have recently shown an increased local formation and secretion of cytokines such as interleukin-6, serum amyloid A 6 and myeloid related protein 8/14 22 (MRP8/14) at the site of coronary occlusion in patients with ACS suggesting that local inflammatory responses are crucial in the development of this syndrome. However, many cellular sources and pathways of activation of these processes remain still unclear. In the present study, we characterize the cellular composition and TLR expression of occluding coronary thrombi and the local cytokine milieu in patients with ACS.
Compared to aortic blood, coronary thrombi contained more CD14-positive monocytes, the most prominent cell type at the site of occlusion. Accordingly, B-cells and T-cells, as well as granulocytes, were less prevalent within thrombotic material. Different levels of CD14-positive monocytes in the peripheral blood of various ACS-subgroups have been described. 23 The fact that monocytes were more prevalent than other leukocytes at the site of coronary occlusion, however, suggests that they specifically accumulate in the thrombus on vulnerable plaques and contribute to the inflammatory reactions during coronary occlusion in ACS.
Nevertheless, the origin and the time-course of appearance of monocytes in intracoronary thrombi remain unclear. Our methodological approach provides a snapshot of the intracoronary status at the time of primary PCI for ACS.
TLR are expressed in atherosclerotic lesions and activated plaques. 24, 25 In our study, also cells within the thrombus exhibited signs of activation, in particular overexpression of TLR.
Compared to leukocytes in the aortic blood, TLR-4 and TLR-2 were overexpressed on local CD14-labelled monocytes and TLR-2 on CD66b-labelled granulocytes. In contrast, no difference was observed in the expression of TLR-3 and TLR-9 between leukocytes obtained from the thrombus and aortic blood. To clarify, whether this induction is ACS-specific or whether this is an intrinsic feature of any in vivo thrombus, we correlated the suspected age of the thrombi with TLR4-expression on monocytes according to the duration of clinical symptoms. We do have a considerable number of early presenters showing a significant activation of the TLR system in coronary thrombi. No correlation whatsoever can be shown over time. The fact that TLR were not activated in monocytes contained in thrombi produced in vitro demonstrates that the inflammatory milieu at the site of coronary occlusion specifically upregulates these receptors. The ACS-specificity of TLR4 overexpression on monocytes at the site of plaque rupture is further supported by the overexpression of TLR-4 in coronary thrombi compared to peripheral blood, and to clots in other settings (peripheral arterial thrombi/emboli, pulmonary embolus) as described above.
The association of CD14 and TLR-4 has been well documented. Indeed, CD14 is required to streamline LPS-induced signalling on TLR-4 by assembling with the MD2-protein 26 (see Figure 6 ). Further, TLR-4 and TLR-2 activity is increased on CD14-positive monocytes in patients with CAD and ACS. [27] [28] [29] Intracellular signal transduction and cross-talk between TLR-2 and TLR-4 30 is complex, but eventually leads to the local release of cytokines and chemokines with proinflammatory, but also anti-inflammatory properties. Of note, particularly repetitive low-level activation of the TLR-system could be protective to damage by promoting a pronounced anti-inflammatory cytokine release to dampen the inflammatory response during subsequent exposure 20, 31 , while marked activation -such as must be the case in ACS -leads to a pronounced inflammatory response. In monocytes, the TLR-4 and the type I interleukin-1 receptor (IL-1R) have a unique intracellular TIR (Toll/IL-1 receptor) signalling domain. In response to activation by the corresponding ligands, TIR domains interact with the TIR domain of the cytoplasmatic adaptor proteins. The subsequent intracellular signalling regulate the production and release of different cytokines 7,32 (see Figure 6 ). In our study, the cytokine milieu at the site of coronary occlusion was characterized by elevated concentrations of chemokines related to an innate immune response (e.g. IL-8, MCP-1, eotaxin, MIP-1α, prominent differences in local cytokine release were identified for IL-12, which underlines the important interplay of innate and adaptive immunity. The production of IL-12 but relative lack of IL-10 suggests that the local environment around the ruptured plaque is conducive for Th1 differentiation, which goes very well together with previously reported findings. 34 Interestingly, classic proinflammatory cytokines such as TNF-α or IL-1β usually released upon TLR-4 activation by LPS were locally not significantly elevated. Similarly, antiinflammatory cytokines that directly and negatively regulate TLR like IL-10 and IL-4 were not elevated at the site of plaque rupture. Nevertheless, we could observe a trend towards local elevation of TNF-α (p=0.06) and IL-4 (p=0.06), which might have become significant without the small potential dilution effects that cannot be excluded. The locally elevated levels of anti-inflammatory IL-1ra suggest a negative feedback-regulation via the TLR-4 associated IL-1 receptor in the TIR-domain. TLR4-TLR2 cross-talk induces a positive feedback signal leading to sustained and amplified activation 30 (see Figure 6 ). Thus, these results suggest a rather specific pattern of expression of cytokines and chemokines after TLRactivation possibly related to the endogenous ligands involved in coronary occlusion in ACS.
The present data suggest that the TLR-4 and TLR-2 signaling pathways on CD14 + monocytes could represent a relevant signal transduction mechanism of innate immunity which mediates local vascular inflammation in ACS. In particular, control thrombi of healthy subjects expressed TLR-4 at lower levels, suggesting that the overexpression of these receptors on monocytes in ACS is indeed disease-specific. It has been suggested that the pleiotropic effects of statins involved in plaque stabilization may be mediated via a reduced expression of TLR-4 on monocytes 35 leading to an attenuated immune response. Hypo-responsive TLR-4 genetic variants have been associated with a reduced risk of myocardial infarction 36, 37 , albeit data on TLR-4-polymorpism are controversial. 38, 39 Nevertheless, TLR-4 may provide a novel therapeutic target. Of note, TLR-ligand based therapies have been considered recently for drug developement 40 and their therapeutic or preventive effects in infectious, malignant, autoimmune, and allergic diseases are under evaluation. 41 However, the complexity and redundancy of the TLR-system, as well as the growing number of endogenous ligands and a number of intracellular signaling molecules and transcription factors regulating pro-and antiinflammatory cytokine production and release limit the predictability of medical interventions within this system. Thus, a better understanding of the role of TLR-ligands and activation, signaling, and feedback-regulation in ACS is necessary.
We acknowledge several limitations of this study. First, we did only investigate inflammatory pathways and mediators within thrombi and local blood samples. The inflammatory processes within the adjacent vessel wall are not addressed in the present study.
The origin of the cells and cytokines accumulating in intracoronary thrombi may therefore be either derived from the circulating blood and/or the underlying vulnerable plaque.
Some dilution effect in particular due to the filling volume of the catheter is likely and cannot be excluded. This raises the question whether negative findings (such as the lack of significant increase in TNF-α or IL-1β, IL-10, IL-4) might be confounded by dilution.
Nevertheless, this limitation does certainly not negate the positive findings. Assumption of any minimal dilution effect, however, implicates reinforcement of significant elevations.
An ultimate proof for the ACS-specifity of TLR upregulation is beyond of the scope of this study. Notwithstanding, when correlating the calculated age of thrombi with TLR4 expression, no influence of thrombus age was found. Although determination of the exact age of thrombi from other clinical settings than ACS, namely peripheral arterial/pulmonary emboli is certainly more difficult (probably they are more often subacute and thus older than coronary thrombi), the difference in TLR4 expression was highly significant and uniform.
This finding further supports the ACS-specificity of our findings. In conclusion, monocytes accumulate in ACS patients within thrombi and markedly and specifically overexpress TLR-4. Together with the local expression patterns of chemokines and cytokines, the increase of TLR-4 reflects a concerted activation of this inflammatory pathway at the site of coronary occlusion in ACS. Through a better understanding of the role of TLR-activation and signaling in ACS, specific TLR-targeted therapies could be beneficial in cardiovascular diseases in the future.
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There are groups of mainly mononuclear leukocytes with high expression (panel A), whereas in regions with mainly polymorphonuclear leukocytes almost no TLR-4 activity was observed (panel B). 
